RESUMEN
Introduction: In renal transplantation, warm ischemia time is the interval from the removal of a procured kidney from ice storage to initiating graft reperfusion. Successful kidney transplantation depends on warm ischemia time. The study aims to find the mean warm ischemia time among kidney transplant patients in a tertiary care centre. Methods: This descriptive cross-sectional study was conducted among kidney transplant patients in a tertiary care centre. Data from 15 December 2012 to 15 October 2022 were collected between 1 December 2022 to 4 January 2023 from the hospital records. Ethical approval was taken from the Nepal Health Research Council (Reference number: 1341). All first-time living-related kidney transplant recipients were included in the study. All the patients undergoing kidney transplants from brain-dead donors were excluded from the study. Convenience sampling method was used. Point estimate and 95% Confidence Interval were calculated. Results: Among 230 patients, the mean warm ischemia time was 35.45±7.35 min. The mean first warm ischemia time was 4.28±2.05 min and the mean second warm ischemia time was 31.27±7.04 min. The mean age of the recipients was 35.14±10.49 years (range 14-64), of which 173 (75.20%) were male and 57 (24.80%) were female. Conclusions: The mean warm ischemia time among kidney transplant patients in a tertiary care centre was similar to the studies done in similar settings. Keywords: kidney transplantation; prevalence; warm ischemia.
Asunto(s)
Trasplante de Riñón , Centros de Atención Terciaria , Isquemia Tibia , Estudios Transversales , Humanos , Donadores Vivos , Adolescente , Adulto Joven , Adulto , Persona de Mediana Edad , Masculino , FemeninoRESUMEN
Anti-thymocyte globulin (ATG) is a pivotal immunosuppressive therapy utilized in the management of T-cell-mediated rejection and steroid-resistant rejection among renal transplant recipients. Commercially available as Thymoglobulin (rabbit-derived, Sanofi, United States), ATG-Fresenius S (rabbit-derived), and ATGAM (equine-derived, Pfizer, United States), these formulations share a common mechanism of action centered on their interaction with cell surface markers of immune cells, imparting immunosuppressive effects. Although the prevailing mechanism predominantly involves T-cell depletion via the com plement-mediated pathway, alternate mechanisms have been elucidated. Optimal dosing and treatment duration of ATG have exhibited variance across ran domised trials and clinical reports, rendering the establishment of standardized guidelines a challenge. The spectrum of risks associated with ATG administration spans from transient adverse effects such as fever, chills, and skin rash in the acute phase to long-term concerns related to immunosuppression, including susceptibility to infections and malignancies. This comprehensive review aims to provide a thorough exploration of the current understanding of ATG, encom passing its mechanism of action, clinical utility in the treatment of acute renal graft rejections, specifically steroid-resistant cases, efficacy in rejection episode reversal, and a synthesis of findings from different eras of maintenance immunosuppression. Additionally, it delves into the adverse effects associated with ATG therapy and its impact on long-term graft function. Furthermore, the review underscores the existing gaps in evidence, particularly in the context of the Banff classification of rejections, and highlights the challenges faced by clinicians when navigating the available literature to strike the optimal balance between the risks and benefits of ATG utilization in renal transplantation.
RESUMEN
Rationale: Corneal neovascularization (CoNV) is a severe complication of various types of corneal diseases, that leads to permanent visual impairment. Current treatments for CoNV, such as steroids or anti-vascular endothelial growth factor agents, are argued over their therapeutic efficacy and adverse effects. Here, we demonstrate that transforming growth factor-ß (TGF-ß)-activated kinase 1 (TAK1) plays an important role in the pathogenesis of CoNV. Methods: Angiogenic activities were assessed in ex vivo and in vitro models subjected to TAK1 inhibition by 5Z-7-oxozeaenol, a selective inhibitor of TAK1. RNA-Seq was used to examine pathways that could be potentially affected by TAK1 inhibition. A gelatin-nanoparticles-encapsulated 5Z-7-oxozeaenol was developed as the eyedrop to treat CoNV in a rodent model. Results: We showed that 5Z-7-oxozeaenol reduced angiogenic processes through impeding cell proliferation. Transcriptome analysis suggested 5Z-7-oxozeaenol principally suppresses cell cycle and DNA replication, thereby restraining cell proliferation. In addition, inhibition of TAK1 by 5Z-7-oxozeaenol blocked TNFα-mediated NFκB signalling, and its downstream genes related to angiogenesis and inflammation. 5Z-7-oxozeaenol also ameliorated pro-angiogenic activity, including endothelial migration and tube formation. Furthermore, topical administration of the gelatin-nanoparticles-encapsulated 5Z-7-oxozeaenol led to significantly greater suppression of CoNV in a mouse model compared to the free form of 5Z-7-oxozeaenol, likely due to extended retention of 5Z-7-oxozeaenol in the cornea. Conclusion: Our study shows the potential of TAK1 as a therapeutic target for pathological angiogenesis, and the gelatin nanoparticle coupled with 5Z-7-oxozeaenol as a promising new eyedrop administration model in treatment of CoNV.
Asunto(s)
Neovascularización de la Córnea , Endotelio Vascular , Lactonas , Quinasas Quinasa Quinasa PAM , Resorcinoles , Animales , Humanos , Masculino , Ratones , Administración Oftálmica , Cápsulas , Ciclo Celular/efectos de los fármacos , Línea Celular , Neovascularización de la Córnea/tratamiento farmacológico , Citocinas/antagonistas & inhibidores , Replicación del ADN/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Endotelio Vascular/efectos de los fármacos , Gelatina , Lactonas/administración & dosificación , Lactonas/farmacología , Lactonas/uso terapéutico , Quinasas Quinasa Quinasa PAM/antagonistas & inhibidores , Ratones Endogámicos C57BL , Nanopartículas , Soluciones Oftálmicas , Resorcinoles/administración & dosificación , Resorcinoles/farmacología , Resorcinoles/uso terapéutico , RNA-SeqRESUMEN
Specific changes in the genome have been accomplished by the revolutionary gene-editing tool known as clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system. The advent of programmable RNA editing CRISPR/Cas nucleases has made this gene-editing tool safer and more precise. Specifically, CasRx, a family member of the Cas13d family, has shown great therapeutic potential. Here, we describe the in vitro methods of utilizing this powerful RNA editing platform and determine the RNA editing efficiencies for CasRx with different forms of guide RNAs (also known as gRNA or sgRNA).
RESUMEN
Angiogenesis plays a critical role in both physiological responses and disease pathogenesis. Excessive angiogenesis can promote neoplastic diseases and retinopathies, while inadequate angiogenesis can lead to aberrant perfusion and impaired wound healing. Transforming growth factor ß activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, is a key modulator involved in a range of cellular functions including the immune responses, cell survival and death. TAK1 is activated in response to various stimuli such as proinflammatory cytokines, hypoxia, and oxidative stress. Emerging evidence has recently suggested that TAK1 is intimately involved in angiogenesis and mediates pathogenic processes related to angiogenesis. Several detailed mechanisms by which TAK1 regulates pathological angiogenesis have been clarified, and potential therapeutics targeting TAK1 have emerged. In this review, we summarize recent studies of TAK1 in angiogenesis and discuss the crosstalk between TAK1 and signaling pathways involved in pathological angiogenesis. We also discuss the approaches for selectively targeting TAK1 and highlight the rationales of therapeutic strategies based on TAK1 inhibition for the treatment of pathological angiogenesis.